KMT2A and leukemia: Finally, another menin-KMT2A inhibitor, Kura Oncology (KO)-539, has been shown to inhibit leukemia growth and prolong survival in KMT2A-rearranged cell lines and in vivo models, earning the FDA Orphan Drug Designation [51].